Get the Stockscreener App
9.9721
1.69%
0.1662
After Hours:
9.97
-0.0021
-0.02%
Global X Genomics Biotechnology Etf stock is traded at $9.9721, with a volume of 58,070.
It is up +1.69% in the last 24 hours and down -6.80% over the past month.
See More
Previous Close:
$9.8059
Open:
$9.87
24h Volume:
58,070
Relative Volume:
0.98
Market Cap:
$N/A
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+1.39%
1M Performance:
-6.80%
6M Performance:
-3.59%
1Y Performance:
-11.63%
1-Day Range:
$9.86
$10.03
1-Week Range:
$9.60
$10.03
52-Week Range:
$9.52
$12.53
Global X Genomics Biotechnology Etf Stock (GNOM) Company Profile
Name
Global X Genomics Biotechnology Etf
Sector
Industry
Phone
-
Address
-
Compare GNOM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GNOM
Global X Genomics Biotechnology Etf
|
9.9721 | 0 | 0 | 0 | 0 | 0.00 |
|
VTI
Vanguard Total Stock Market Etf
|
293.06 | 417.53B | 0 | 0 | 0 | 0.00 |
|
SPY
Spdr S P 500 Etf Trust
|
591.95 | 372.57B | 0 | 0 | 0 | 0.00 |
|
IVV
Ishares Core S P 500 Etf
|
594.61 | 253.41B | 0 | 0 | 0 | 0.00 |
|
VB
Vanguard Small Cap Etf
|
243.49 | 160.59B | 0 | 0 | 0 | 0.00 |
|
QQQ
Invesco Qqq Trust Series 1
|
518.58 | 124.43B | 0 | 0 | 0 | 0.00 |
Global X Genomics Biotechnology Etf Stock (GNOM) Latest News
Stifel Financial Corp Reduces Stock Position in Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) - Defense World
Jane Street Group LLC Sells 16,550 Shares of Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) - Defense World
Learn to Evaluate (GNOM) using the Charts - Stock Traders Daily
Rockefeller Capital Management L.P. Acquires Shares of 18,186 Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) - Defense World
Best-Performing ETF Areas of Last Week - Yahoo Finance
Atria Investments Inc Invests $122,000 in Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) - Defense World
When (GNOM) Moves Investors should Listen - Stock Traders Daily
Top Tech ETFs Right Now - Benzinga
5 Small-cap Biotech ETFs to Watch (Updated 2024) - Investing News Network
Newport Capital Group LLC Acquires Shares of 21,305 iShares 3-7 Year Treasury Bond ETF (NASDAQ:IEI) - Defense World
Top ETFs Tracking CRISPR Gene Editing - The Motley Fool
Top Canadian Genetics Stocks of 2024 - The Motley Fool Canada
How To Avoid The Worst Sector ETFs 3Q24 - Forbes
Investing in Nobel Prize Achievements – CRISPR For Precise Genetic Engineering - Securities.io
(GNOM) Proactive Strategies - Stock Traders Daily
3 Gene Editing Stocks with Potential to Transform Medicine - InvestorPlace
BioTech & Genomics ETFs Shine Amid Sector Rotation - Trackinsight
Time for Healthcare ETFs? - Yahoo Finance
Biotech ETFs See Uptick Amid Positive Market Signs - Trackinsight
The 3 Best Gene Editing Stocks to Buy in July 2024 - InvestorPlace
4 Up-and-Coming Small-Cap Biotech Stocks to Watch - Investing.com
7 Best Biotech ETFs to Buy Now - U.S News & World Report Money
The Next Big Theme: June 2024 - Global X
9 Best Biotech ETFs for 2024 - MSN
Genomics Game-Changers: 3 Stocks Unlocking the Secrets of Life - InvestorPlace
3 Gene Editing Stocks with the Potential to Make You an Overnight Millionaire - InvestorPlace
In the Pipeline: Top Drug Candidates for FDA Approval in 2024 - Nasdaq
The Next Big Theme: April 2024 - Global X
Investing in Pharma: How to Spot Leading Drug Candidates - Global X
CTNM Stock: Discover Biotech Investing Potential with Contineum Therapeutics - Value the Markets
GNOM: Genomics Still Waiting For Its 'ChatGPT' Moment (NASDAQ:GNOM) - Seeking Alpha
3 Stocks That Could Be the Next Big Thing in Gene Editing - InvestorPlace
The Next Big Theme: March 2024 - Global X
Why Gene Editing Could Be Worth $120 Billion by 2027 - Opto RoW
Biotech Funds Underperform the Broader Market - Trackinsight
Gene Therapy: A Cure for Cancer? - Opto RoW
3 Gene Editing Stocks With Unprecedented Surge Potential - Yahoo Finance
3 Once-in-a-Lifetime Gene Editing Stocks with Unprecedented Surge Potential - InvestorPlace
The Next Big Theme: January 2024 - Global X
3 Biotech ETFs to Bet on Now - Nasdaq
M&A Watch: 3 Drug Maker Stocks That Could Be Acquired in 2024 - InvestorPlace
The Next Big Theme: December 2023 - Global X
VettaFi Voices On: The Outlook for 2024 - ETF Trends
The Next Big Theme: November 2023 - Global X
The Genomic Medicine Revolution - Global X
This Rally Seemed To Come Out Of Nowhere. It Didn’t. - Finimize
AI Applications in Healthcare: From Drug Discovery to Patient Care - Global X
How to Invest in Genetics - Investing News Network
Top Biotech Stocks to Invest InDiscover the Best Biotech Stocks to Watch - Opto RoW
3 Gene Editing Stocks to Generate Super-Charged Gains - Markets Insider
Global X Genomics Biotechnology Etf Stock (GNOM) Financials Data
There is no financial data for Global X Genomics Biotechnology Etf (GNOM). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.77%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):